Saniona AB (30S) AI Stock Analysis

Saniona AB

(Frankfurt:30S)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong profitabilityThe sharp shift from heavy losses in 2021–2023 to very high profitability in 2025 and 2026 TTM demonstrates substantial recent earnings power. If supported by recurring business activity, these margins can fund development, strengthen resilience, and support continued investment in the pipeline.

Negative Factors

Revenue volatilityThe sharp latest TTM revenue decline following strong prior-year growth makes the current earnings base difficult to forecast. In a biotech model that may include milestones or licensing revenue, inconsistent top-line performance can weaken visibility into recurring operations and reduce confidence in sustaining recent profitability.

Saniona AB (30S) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 140.16M
Dividend Yield: ―
Average Volume (3M): 500
Price to Earnings (P/E): 8.3
Beta (1Y): 0.70
Revenue Growth: 29.05%
EPS Growth: -30.33%
Country: Germany
Employees: 44
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Saniona AB Business Overview & Revenue Model

Company Description

Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disord...

Saniona AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:30S against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:CAMX	80Outperform	SEK 40.76B	59.09	15.54%	―	<0.01%	-6.75%
SE:BIOA.B	65Neutral	SEK 28.15B	266.55	5.18%	0.68%	-46.09%	-90.13%
SE:ALZCUR	55Neutral	SEK 882.54M	42.87	65.99%	―	―	―
SE:HNSA	55Neutral	SEK 4.00B	-5.00	―	―	-3.57%	8.84%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:30S and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:30S	Saniona AB	0.98	-0.43	-30.54%
SE:HNSA	Hansa Biopharma	39.34	8.94	29.41%
SE:MVIR	Medivir	1.55	1.04	201.56%
SE:CAMX	Camurus AB	673.00	62.00	10.15%
SE:ALZCUR	AlzeCure Pharma AB	6.40	4.54	243.16%
SE:BIOA.B	BioArctic AB Class B	317.20	34.68	12.27%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Saniona AB AI Stock Analysis